Rimegepant 75 MG
Sponsors
Danish Headache Center, Pfizer, Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine, University of Florence, Medstar Health Research Institute
Conditions
EndometriosisEndometriosis-related PainMigraineMigraine With AuraMigraine Without AuraTrigger Induced Migraine
Phase 2
Phase 3
Phase 4
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
TerminatedNCT05211154
Start: 2022-05-05End: 2025-04-30Updated: 2025-09-29
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RecruitingNCT07301008
Start: 2025-09-09End: 2027-01-31Target: 60Updated: 2025-12-24
Unknown Phase
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
CompletedNCT05709106
Start: 2023-01-11End: 2025-04-09Updated: 2026-02-05
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
RecruitingNCT06409832
Start: 2024-03-26End: 2027-09-01Target: 100Updated: 2026-06-11